Tissue factor-activated Factor VII complex (TF-FVIIa) (TF-FVIIa)

The Tissue factor-activated Factor VII (TF-FVIIa) complex, also known as the extrinsic tenase complex, is the primary initiator of the blood coagulation cascade (StatPearls, 2023). Tissue factor (TF) is a transmembrane glycoprotein that is normally sequestered from the blood but becomes exposed upon vascular injury, where it binds to circulating Factor VII or activated Factor VIIa with high affinity (UniProt, P13726). Once formed, this complex acts as a potent serine protease that activates Factor IX and Factor X, ultimately leading to the production of thrombin and the formation of a stable fibrin clot (PubMed, PMID: 15170391). Beyond its role in hemostasis, the TF-FVIIa complex triggers intracellular signaling through the activation of protease-activated receptors (PARs), influencing processes such as inflammation, angiogenesis, and tumor metastasis (PubMed, PMID: 22403440). In clinical practice, recombinant activated Factor VII (rFVIIa) is used as a bypassing agent to treat bleeding in hemophilia patients with inhibitors (FDA, NovoSeven Label). Conversely, inhibitors of the TF-FVIIa complex are being investigated for their potential to treat thrombotic disorders and certain cancers where TF is overexpressed (Journal of Thrombosis and Haemostasis, 2015). The complex's activity is naturally regulated by Tissue Factor Pathway Inhibitor (TFPI), which forms a quaternary complex to shut down further Factor X activation (PubMed, PMID: 11007014). Therapeutic targeting of this complex requires a delicate balance to prevent excessive bleeding while controlling pathological thrombosis or signaling (Nature Reviews Drug Discovery, 2004).

Other names

Factor III-Factor VIIa complexThromboplastin-Factor VIIa complexCD142-F7 complexExtrinsic tenase complexTissue factor receptor

The complex initiates the extrinsic pathway of the coagulation cascade by proteolytically activating Factor IX and Factor X, leading to thrombin generation and fibrin clot formation (StatPearls, 2023).